{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:47:46Z","timestamp":1785577666193,"version":"3.56.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Disseminated Bacillus Calmette-Gu\u00e9rin (BCG) infection is a rare complication of intravesical BCG therapy, affecting both immunocompetent and immunocompromised patients. We present a case of disseminated BCG infection in an 86-year-old man undergoing immune checkpoint inhibitor therapy for relapsed Hodgkin lymphoma and concomitant intravesical BCG therapy for non-muscle-invasive bladder cancer. The patient developed a progressive mycotic abdominal aortic aneurysm, psoas abscess, and vertebral osteomyelitis.\n                    <jats:italic>Mycobacterium bovis<\/jats:italic>\n                    BCG was confirmed via Polymerase Chain Reaction (PCR) and mycobacterial culture from a psoas abscess biopsy. Despite appropriate antimycobacterial therapy and multiple attempts at abscess drainage, his condition deteriorated, ultimately leading to his death. This case highlights the challenges of diagnosing disseminated BCG infection, which can mimic malignancy, and suggests a possible link between immune checkpoint inhibitors and BCG dissemination. Clinicians should maintain a high index of suspicion for BCG-related complications, particularly among those receiving immune-modulating therapies.\n                  <\/jats:p>","DOI":"10.1186\/s12879-025-11511-3","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T18:54:34Z","timestamp":1763060074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Disseminated Bacillus Calmette-Guerin infection following concurrent intravesical BCG therapy and immune checkpoint inhibitior therapy: a case report"],"prefix":"10.1186","volume":"25","author":[{"given":"Martin","family":"Plymoth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charbel Wehbe","family":"C.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn","family":"Crighton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indy","family":"Sandaradura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"issue":"6","key":"11511_CR1","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1086\/513642","volume":"24","author":"EA Talbot","year":"1997","unstructured":"Talbot EA, Perkins MD, Silva SF, Frothingham R. Disseminated Bacille Calmette-Gu\u00e9rin disease after vaccination: case report and review. Clin Infect Dis. 1997;24(6):1139\u201346.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"11511_CR2","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","volume":"147","author":"DL Lamm","year":"1992","unstructured":"Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of Bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992;147(3):596\u2013600.","journal-title":"J Urol"},{"issue":"4","key":"11511_CR3","doi-asserted-by":"publisher","first-page":"e13084","DOI":"10.1111\/sji.13084","volume":"94","author":"E Soyak Aytekin","year":"2021","unstructured":"Soyak Aytekin E, Keskin A, Tan C, Yal\u00e7\u0131n E, Dogru D, Ozcelik U, et al. Differential diagnosis of primary immunodeficiency in patients with bcgitis and bcgosis: A single-centre study. Scand J Immunol. 2021;94(4):e13084.","journal-title":"Scand J Immunol"},{"issue":"5","key":"11511_CR4","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/bju.12562","volume":"113","author":"L Hanna","year":"2014","unstructured":"Hanna L, Ubee SS, Boddy J, Cooke PW. Efficacy and complications of intravesical BCG in immunocompromised patients. BJU Int. 2014;113(5):691\u20133.","journal-title":"BJU Int"},{"issue":"1","key":"11511_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/1097-0142(197807)42:1<167::AID-CNCR2820420128>3.0.CO;2-D","volume":"42","author":"PS Ritch","year":"1978","unstructured":"Ritch PS, McCredie KB, Gutterman JU, Hersh EM. Disseminated BCG disease associated with immunotherapy by scarification in acute leukemia. Cancer. 1978;42(1):167\u201370.","journal-title":"Cancer"},{"issue":"2","key":"11511_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1086\/344908","volume":"36","author":"OY Gonzalez","year":"2003","unstructured":"Gonzalez OY, Musher DM, Brar I, Furgeson S, Boktour MR, Septimus EJ, et al. Spectrum of Bacille Calmette-Gu\u00e9rin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis. 2003;36(2):140\u20138.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"11511_CR7","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1128\/JCM.41.4.1637-1650.2003","volume":"41","author":"RC Huard","year":"2003","unstructured":"Huard RC, Lazzarini LC, Butler WR, van Soolingen D, Ho JL. PCR-based method to differentiate the subspecies of the Mycobacterium tuberculosis complex on the basis of genomic deletions. J Clin Microbiol. 2003;41(4):1637\u201350.","journal-title":"J Clin Microbiol"},{"key":"11511_CR8","doi-asserted-by":"publisher","first-page":"100152","DOI":"10.1016\/j.jctube.2020.100152","volume":"19","author":"RK Meyer","year":"2020","unstructured":"Meyer RK, Williams SJ, Lee TY. Mycobacterium Bovis infection of a femorofemoral bypass graft following intravesical Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy. J Clin Tuberc Other Mycobact Dis. 2020;19:100152.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"6","key":"11511_CR9","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/bju.14793","volume":"124","author":"ES Larsen","year":"2019","unstructured":"Larsen ES, Nordholm AC, Lillebaek T, Holden IK, Johansen IS. The epidemiology of Bacille Calmette-Gu\u00e9rin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study. BJU Int. 2019;124(6):910\u20136.","journal-title":"BJU Int"},{"issue":"1","key":"11511_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.23736\/S2724-6051.24.05910-X","volume":"77","author":"A Artiles Medina","year":"2025","unstructured":"Artiles Medina A, Subiela JD, Tagalos Mu\u00f1oz A, Tato D\u00edez M, M\u00ednguez Ojeda C, L\u00f3pez Curtis D, et al. Clinical outcomes of BCG infections in patients undergoing intravesical immunotherapy for non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Minerva Urol Nephrol. 2025;77(1):13\u201324.","journal-title":"Minerva Urol Nephrol"},{"issue":"1","key":"11511_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.urolonc.2023.09.010","volume":"42","author":"AM Durant","year":"2024","unstructured":"Durant AM, Choudry MM, Madura G, Mi L, Faraj KS, Tyson MD. Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions. Urol Oncol. 2024;42(1):21\u20138.","journal-title":"Urol Oncol"},{"issue":"9","key":"11511_CR12","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jiac.2023.05.017","volume":"29","author":"R Takase","year":"2023","unstructured":"Takase R, Hagiya H, Fujimori T, Yokoyama Y, Iio K, Honda H, et al. Super acute-onset disseminated BCG infection: A case report. J Infect Chemother. 2023;29(9):919\u201321.","journal-title":"J Infect Chemother"},{"issue":"15","key":"11511_CR13","doi-asserted-by":"publisher","first-page":"E467","DOI":"10.1503\/cmaj.171214","volume":"190","author":"S Rohailla","year":"2018","unstructured":"Rohailla S, Kitchlu A, Wheatcroft M, Razak F. Mycotic aneurysm formation after Bacillus Calmette-Gu\u00e9rin instillation for recurrent bladder cancer. CMAJ. 2018;190(15):E467\u201371.","journal-title":"CMAJ"},{"key":"11511_CR14","doi-asserted-by":"publisher","first-page":"100149","DOI":"10.1016\/j.jctube.2020.100149","volume":"19","author":"R Waked","year":"2020","unstructured":"Waked R, Choucair J, Chehata N, Haddad E, Saliba G. Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) treatment\u2019s severe complications: A single institution review of incidence, presentation and treatment outcome. J Clin Tuberc Other Mycobact Dis. 2020;19:100149.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"11511_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3389\/fimmu.2018.00411","volume":"9","author":"J Da Gama Duarte","year":"2018","unstructured":"Da Gama Duarte J, Parakh S, Andrews MC, Woods K, Pasam A, Tutuka C, et al. Autoantibodies May predict Immune-Related toxicity: results from a phase I study of intralesional Bacillus Calmette-Gu\u00e9rin followed by ipilimumab in patients with advanced metastatic melanoma. Front Immunol. 2018;9:411.","journal-title":"Front Immunol"},{"key":"11511_CR16","doi-asserted-by":"crossref","unstructured":"Cook V, Singla AA, Herlihy D, Mohabbat W, Fisher C, Puttaswamy V. Successful endovascular exclusion of Mycobacterium bovis mycotic aneurysm following intravesical bacille Calmette-Guerin therapy. J Surg Case Rep. 2022;(10):rjac426.","DOI":"10.1093\/jscr\/rjac426"},{"issue":"10","key":"11511_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.4066\/AMJ.2015.2475","volume":"8","author":"LP Aitchison","year":"2015","unstructured":"Aitchison LP, Jayanetti V, Lindstrom ST, Sekel R. Myobacterium Bovis peri-prosthetic hip infection with successful prosthesis retention following intravesical BCG therapy for bladder carcinoma. Australas Med J. 2015;8(10):307\u201314.","journal-title":"Australas Med J"},{"key":"11511_CR18","first-page":"22","volume":"4","author":"C Garcia","year":"2016","unstructured":"Garcia C, Jina H, Bergersen P, Chalasani V. Bladder Contracture - A rare and serious side effect of intravesical Bacillus Calmette-Gu\u00e9rin therapy. Urol Case Rep. 2016;4:22\u20134.","journal-title":"Urol Case Rep"},{"key":"11511_CR19","doi-asserted-by":"crossref","unstructured":"Ribeiro L, Rajendran S, Stenson K, Loftus I. Rare case of a proximal descending thoracic aorta mycotic aneurysm following intravesical BCG injections for the treatment of bladder cancer. BMJ Case Rep. 2019;12(12):e231595.","DOI":"10.1136\/bcr-2019-231595"},{"issue":"10","key":"11511_CR20","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1111\/imj.12876","volume":"45","author":"N Nayar","year":"2015","unstructured":"Nayar N, Briscoe K. Systemic Bacillus Calmette-Guerin sepsis manifesting as hypercalcaemia and thrombocytopenia as a complication of intravesical Bacillus Calmette-Guerin therapy. Intern Med J. 2015;45(10):1091\u20132.","journal-title":"Intern Med J"},{"key":"11511_CR21","first-page":"102317","volume":"46","author":"A Jain","year":"2023","unstructured":"Jain A. Pott\u2019s disease post intravesical BCG. Urol Case Rep. 2023;46:102317.","journal-title":"Urol Case Rep"},{"key":"11511_CR22","unstructured":"HealthStats NSW. Population estimates local health districts. In: NSW Government. 2023."},{"key":"11511_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.avsg.2022.01.027","volume":"83","author":"KKF Ho","year":"2022","unstructured":"Ho KKF, Lal V, Hagley D, Bingley J. Systematic review of case reports of Bacillus Calmette-Guerin vascular infections. Ann Vasc Surg. 2022;83:369\u201377.","journal-title":"Ann Vasc Surg"},{"issue":"2","key":"11511_CR24","doi-asserted-by":"publisher","first-page":"ofaf070","DOI":"10.1093\/ofid\/ofaf070","volume":"12","author":"U Manickavasagar","year":"2025","unstructured":"Manickavasagar U, Nel H, Seet J, Varrone L, Keehner T, McCann R, et al. Mycobacterium Bovis infections following intravesical Bacillus Calmette-Gu\u00e9rin instillation for bladder cancer in Western australia: A 22-Year retrospective review. Open Forum Infect Dis. 2025;12(2):ofaf070.","journal-title":"Open Forum Infect Dis"},{"key":"11511_CR25","doi-asserted-by":"crossref","unstructured":"Watts MR, Taylor PC, Sintchenko V, Whelan CM, Farnsworth RH, Jones P, et al. editors. \u2018s choice: Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Gu\u00e9rin used for immunotherapy in bladder cancer. Clin Infect Dis.\u00a02011; 52(1):86\u201388.","DOI":"10.1093\/cid\/ciq002"},{"key":"11511_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ITT.S284988","volume":"11","author":"AY Lin","year":"2022","unstructured":"Lin AY, Schnitter JM, Gordon LI. Immune checkpoint Blockade for the treatment of hodgkin lymphoma. Immunotargets Ther. 2022;11:1\u201310.","journal-title":"Immunotargets Ther"},{"key":"11511_CR27","doi-asserted-by":"publisher","first-page":"696268","DOI":"10.3389\/fimmu.2021.696268","volume":"12","author":"V Gies","year":"2021","unstructured":"Gies V, Dieudonn\u00e9 Y, Morel F, Sougakoff W, Carapito R, Martin A, et al. Case report: acquired disseminated BCG in the context of a delayed immune reconstitution after hematological malignancy. Front Immunol. 2021;12:696268.","journal-title":"Front Immunol"},{"issue":"8","key":"11511_CR28","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1080\/00365540500452473","volume":"38","author":"A Kroidl","year":"2006","unstructured":"Kroidl A, Huck K, Weinspach S, Gudowius S, Mackenzie CR, Oette M, et al. Immune reconstitution inflammatory syndrome (IRIS) due to Bacille calmette Guerin (BCG) in an HIV-positive child. Scand J Infect Dis. 2006;38(8):716\u20138.","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"11511_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12981-024-00614-7","volume":"21","author":"P Machava","year":"2024","unstructured":"Machava P, Joaquim W, Borrell J, Richardson S, Cassia U, Sidat M, et al. Severe BCG immune reconstitution inflammatory syndrome lymphadenitis successfully managed with pre-antiretroviral counseling and a non-surgical approach: a case report. AIDS Res Ther. 2024;21(1):25.","journal-title":"AIDS Res Ther"},{"issue":"5","key":"11511_CR30","doi-asserted-by":"publisher","first-page":"ofaa126","DOI":"10.1093\/ofid\/ofaa126","volume":"7","author":"K Fujita","year":"2020","unstructured":"Fujita K, Yamamoto Y, Kanai O, Okamura M, Hashimoto M, Nakatani K, et al. Incidence of active tuberculosis in lung cancer patients receiving immune checkpoint inhibitors. Open Forum Infect Dis. 2020;7(5):ofaa126.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"11511_CR31","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.21037\/jtd-23-1395","volume":"16","author":"A Vaddi","year":"2024","unstructured":"Vaddi A, Hulsebus HJ, O\u2019Neill EL, Knight V, Chan ED. A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does goldilocks have the answer? J Thorac Dis. 2024;16(2):1601\u201324.","journal-title":"J Thorac Dis"},{"issue":"6","key":"11511_CR32","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","volume":"25","author":"A Necchi","year":"2024","unstructured":"Necchi A, Roumigui\u00e9 M, Kamat AM, Shore ND, Boormans JL, Esen AA, et al. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024;25(6):720\u201330.","journal-title":"Lancet Oncol"},{"issue":"6","key":"11511_CR33","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","volume":"84","author":"PC Black","year":"2023","unstructured":"Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, et al. Phase 2 trial of Atezolizumab in Bacillus Calmette-Gu\u00e9rin-unresponsive High-risk Non-muscle-invasive bladder cancer: SWOG S1605. Eur Urol. 2023;84(6):536\u201344.","journal-title":"Eur Urol"},{"issue":"4suppl","key":"11511_CR34","doi-asserted-by":"publisher","first-page":"TPS722","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS722","volume":"42","author":"ND Shore","year":"2024","unstructured":"Shore ND, Nishiyama H, Shariat SF, Steinberg G, Kamat AM, Alanee SR, et al. Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Gu\u00e9rin (BCG) with or without pembrolizumab for high-risk (HR) non\u2013muscle-invasive bladder cancer (NMIBC) that persists\/recurs after BCG induction. J Clin Oncol. 2024;42(4suppl):TPS722\u2013722.","journal-title":"J Clin Oncol"},{"key":"11511_CR35","doi-asserted-by":"publisher","unstructured":"Roupret M, Neuzillet Y, Bertaut A, Pignot G, Houede N, Champiat S, et al. ALBAN: An open label, randomized, phase III trial, evaluating efficacy of atezolizumab in addition to one year BCG (bacillusCalmette-Guerin) bladder instillation in BCG-naive patients withhigh-risk nonmuscle invasive bladder cancer (AFU-GETUG 37). J Clin Oncol .\u00a0 2019;37:TPS4589-TPS4589. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS4589.","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4589"},{"issue":"14","key":"11511_CR36","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2217\/fon-2023-0271","volume":"20","author":"GD Steinberg","year":"2024","unstructured":"Steinberg GD, Shore ND, Redorta JP, Galsky MD, Bedke J, Ku JH, et al. CREST: phase III study of Sasanlimab and Bacillus Calmette-Gu\u00e9rin for patients with Bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk non-muscle-invasive bladder cancer. Future Oncol. 2024;20(14):891\u2013901.","journal-title":"Future Oncol"},{"key":"11511_CR37","doi-asserted-by":"crossref","unstructured":"Maas M, Hilsendecker A, Pertoll A, St\u00fchler V, Walz S, Rausch S et al. PD-L1 expression in High-Risk Non-Muscle-Invasive bladder cancer is influenced by intravesical Bacillus Calmette-Gu\u00e9rin (BCG) therapy. Cancers (Basel). 2024; 16(7).","DOI":"10.3390\/cancers16071356"},{"key":"11511_CR38","unstructured":"Shore ND, Powles TB, Bedke J, Galsky MD, Palou Redorta J, Ku JH et al. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cance"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11511-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11511-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11511-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:59:13Z","timestamp":1781614753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-11511-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11511"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11511-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The case report design was reviewed by the Western Sydney Local Health District Human Research Ethics Committee, and deemed to conform to standards currently applied in the country of origin (Australia). This case report was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient and their next of kin for publication of this study and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1575"}}